Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

Day 1 :
MONDAY, MARCH 23, 2026
08:30 - 09:30
REGISTRATION AND MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
VERSATILITY OF TRANSCRIPTION FACTORS AS GENE EDITING TARGETS FOR PRECISION ONCOLOGY
Natalia Rivera-Torres
ChristianaCare Gene Editing Institute

Natalia Rivera-Torres

ChristianaCare Gene Editing Institute

  • Evaluating transcription factors as durable gene editing targets to expand precision oncology
  • Disrupting oncogenesis with multifactor disruptions through multiplex transcription factor editing
  • Optimizing gene editing to interrogate key pathways of oncogenesis and prioritize targets
10:05 - 10:10
Q&A SESSION ON TRANSCRIPTION FACTORS AND ONCOGENESIS
10:10 - 10:40
SPEED NETWORKING SESSION
  • Exchange business cards and get connected in short one-to-one meetings
  • Start the conversation to arrange a more formal meeting later on in the conference
  • Share your professional background and discuss your biggest business issues – don't forget your business cards!
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:30
PANEL DISCUSSION ON CRISPR MEDICINE
11:30 - 11:55
THE CRISPR LANDSCAPE: REGULATIONS AND PAYOR OUTLOOK EVOLUTIONS
James Boiani
Epstein Becker & Green

James Boiani

Epstein Becker & Green

  • Emerging promises of CRISPR and its potential in transforming healthcare solutions
  • Navigating regulatory and payment pathways under changing governmental administrations
  • Providing early insights and future predictions for the CRISPR landscape post-policy changes
11:55 - 12:00
Q&A SESSION ON REGULATIONS AND PAYOR OUTLOOK IN CRISPR
12:00 - 13:30
NETWORKING LUNCH AND VISITING THE CRISPR MEDICINE EXHIBITION
13:30 - 13:55
PRE-CLINICAL RESEARCH TO CLINICAL PROGRAMS: GRNA MANUFACTURING & GENOME EDITING
Jenna Danna
Integrated DNA Technologies

Jenna Danna

Integrated DNA Technologies

  • Providing end-to-end off-target analysis services to ensure genome editing precision
  • Highlighting a novel HDR-enhancing protein shown to produce no adverse effects in studies
  • Characterizing high-quality gRNAs to support reliable gene editing outcomes
13:55 - 14:00
Q&A SESSION ON ADVANCING GRNA QUALITY & GENOME EDITING SAFETY
14:00 - 14:30
RESERVED PRESENTATION
14:30 - 15:00
AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA
15:00 - 15:25
CHEMICALLY LIGATED GUIDES TO MINIMIZE OFF-TARGET IMPURITIES
Minghong Zhong
GeneLancet Biosciences

Minghong Zhong

GeneLancet Biosciences

  • Exploring chemically ligated guide RNA (lgRNA) for enhanced CRISPR precision and scalability
  • Highlighting limitations of current sgRNA production methods, including low purity and yields
  • Introducing lgRNA technology with nNt-Linkers for high-quality manufacturing at large scales
  • Detailing non-chromatographic manufacturing processes for scalable, high-quality lgRNA libraries
15:25 - 15:30
Q&A SESSION ON ADDRESSING CRISPR PRODUCTION CHALLENGES
15:30 - 15:55
IN VIVO CRISPR EDITING FOR CORNEAL DYSTROPHY FROM NHP TO FIRST PATIENT
Yu Cao
GenEditBio Limited

Yu Cao

GenEditBio Limited

  • Pioneering in vivo CRISPR RNP therapy for TGFBI granular corneal dystrophy as once-and-done
  • Validating safety in non-human primates with intrastromal delivery and minimal off-targets
  • Initiating the first-in-human trial of GCD CRISPR-based gene therapy for corneal dystrophy
15:55 - 16:00
Q&A SESSION ON CRISPR-BASED GENE THERAPY FOR CORNEAL DYSTROPHY
16:00 - 16:25
PROGRAMMABLE RNA-TRIGGERED CELL ELIMINATION USING CRISPR-CAS12A2
Jared Thompson
University of Utah School of Medicine

Jared Thompson

University of Utah School of Medicine

  • Programming a CRISPR protein with DNA shredding to eliminate cells directed by target RNA
  • Inducing precise DNA damage with Cas12a2 to kill lung cancer cells at single-nucleotide specificity
  • Enriching gene edits by deploying Cas12a2 as a selection platform to improve editing outcomes
16:25 - 16:30
Q&A SESSION ON CAS12A2 FOR RNA-TRIGGERED CELL ELIMINATION
16:30 - 17:30
NETWORKING DRINKS RECEPTION
Day 2 :
TUESDAY, MARCH 24, 2026
09:00 - 09:30
MORNING REFRESHMENTS
09:30 - 09:40
OPENING ADDRESS
09:40 - 10:05
CMC STRATEGIES FOR GENE EDITING DELIVERY: FROM BENCH TO SCALABLE THERAPIES
Kok-Seong Lim
Independent speaker

Kok-Seong Lim

Independent speaker

  • Contrasting AAV and LNP manufacturability and scalability for reliable in vivo editing
  • Right-sizing release, stability, and characterization from IND through pivotal studies
  • Aligning with FDA and EMA expectations on vectors, LNPs, and comparability strategy
10:05 - 10:10
Q&A SESSION ON CMC STRATEGIES FOR GENE DELIVERY
10:10 - 10:35
GENE EDITING IN PROSTATE CANCER MODELS
Xiaofeng Su
Uniformed Services University

Xiaofeng Su

Uniformed Services University

  • Targeting mutations in DNA damage repair genes to study prostate cancer development
  • Engineering organoid models to replicate oncogenesis for advanced drug discovery
10:35 - 10:40
Q&A SESSION ON GENE EDITING IN CANCER MODELS
10:40 - 11:00
MORNING COFFEE BREAK IN THE EXHIBIT AREA
11:00 - 11:25
LEVERAGING REIMBURSEMENT MODELS FOR MARKET ACCESS IN THERAPEUTICS
Michael Sherman
Sherman Healthcare Solutions

Michael Sherman

Sherman Healthcare Solutions

  • Addressing market access barriers and innovative reimbursement models for high-cost therapies
  • Exploring implications of risk-based agreements for CRISPR-based and transformative products
11:25 - 11:30
Q&A SESSION ON REIMBURSEMENT MODELS FOR CRISPR THERAPEUTICS
11:30 - 11:55
ORTHOSTERIC AND ALLOSTERIC CONTROL OF CAS ENZYMES AT THE ATOMIC LEVEL
George Lisi
Brown University

George Lisi

Brown University

  • Deciphering allosteric signal transmission in Cas effectors and anti-CRISPR control at atomic scale
  • Elucidating molecular rules that enhance specificity and expand PAM recognition breadth
  • Tuning protein–guide RNA interfaces to modulate activity, reactivity, and functional range
  • Interrogating thermostable Cas systems active in physiological contexts to broaden use
11:55 - 12:00
Q&A SESSION ON MOLECULAR CONTROL OF CAS SPECIFICITY
12:00 - 12:25
CRISPR SCREEN FOR TARGETING ALZHEIMER'S USING HUMAN BRAIN ORGANOIDS
Rigel Chan
UMass Chan Medical School

Rigel Chan

UMass Chan Medical School

  • Studying Alzheimer's disease linked to amyloid beta plaques and neuroinflammation
  • Developing a human brain organoid model showing HSV-1's role in amyloid beta elevation
  • Performing genome-wide CRISPR screens to identify genes reducing amyloid beta expression
  • Identifying promising therapeutic targets for addressing Alzheimer's disease
12:25 - 12:30
Q&A SESSION ON BRAIN ORGANOIDS AND ALZHEIMER'S DISEASE
12:30 - 12:45
FEEDBACK & RAFFLE DRAW
12:45 - 14:00
NETWORKING LUNCH

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.